Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Understanding Where A Catalyst For Valuation Expansion Will Come From
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald maintains a 'Hold' on Dendreon (NASDAQ: DNDN) price target lowered from $14 to $12.
Analyst, Mara Goldstein, said, "Provenge's struggle to find a place in the treatment arsenal for prostate cancer may get harder as Zytiga, an anti-androgen, reported that its trial in asymptomatic or mildly symptomatic patients with metastatic castrate resistant prostate cancer (HRPC) who have not received chemotherapy met the criteria for early stopping in a large-scale clinical trial in this setting. This patient population is competitive to Provenge's."
"With shares trading off heavily, the key question is in understanding where a catalyst for valuation expansion will come from. And while we can make the case that the shares are not unreasonably valued at 2.5x cash and 3.3x 2013 revenue, we have less conviction as to where and when such a catalyst will emerge." (Cantor lowers FY13 loss from (1.15) to (1.76) and FY13 revs from $538m to $466.3m)
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.12 yesterday.
Analyst, Mara Goldstein, said, "Provenge's struggle to find a place in the treatment arsenal for prostate cancer may get harder as Zytiga, an anti-androgen, reported that its trial in asymptomatic or mildly symptomatic patients with metastatic castrate resistant prostate cancer (HRPC) who have not received chemotherapy met the criteria for early stopping in a large-scale clinical trial in this setting. This patient population is competitive to Provenge's."
"With shares trading off heavily, the key question is in understanding where a catalyst for valuation expansion will come from. And while we can make the case that the shares are not unreasonably valued at 2.5x cash and 3.3x 2013 revenue, we have less conviction as to where and when such a catalyst will emerge." (Cantor lowers FY13 loss from (1.15) to (1.76) and FY13 revs from $538m to $466.3m)
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
- Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
